Contact Information
Please direct all questions to:

Public Health Agency of Canada
CNISP Surveillance
E-mail: phac.cnisp-pcsin.aspc@canada.ca

Working Group
John Bautista, Lizanne Beique* (Observer), James Brooks*, Kelly Choi* (Epi lead), Jeannette Comeau, John Conly (Chair), Bruce Dalton, Johan Delport, Rita Dhami, Joanne Embree, Yannick Émond, Gerald Evans, Charles Frenette, Susan Fryters, Greg German, Denise Gilby* (Observer), Jennifer Grant, Jennifer Happe†, Kevin Katz, Pamela Kibsey, Justin Kosar, Joanne Langley, Bonita Lee, Marie-Astrid Lefebvre, Jerome Leis, Cheryl Marinsky* (Observer), Allison McGeer, Susan McKenna, Michael Mulvey‡, Heather Neville, Linda Pelude* (Epi Lead), Wallis Rudnick* (on leave), Michelle Science (Chair), Kathy Slayter, Kathy Suh, Daniel Thirion (Chair), Alena Tse-Chang, Karl Weiss

* Public Health Agency of Canada (PHAC)
‡ National Microbiology Lab (NML)
† IPAC
# Table of Contents

**BACKGROUND** .......................................................................................................................... 3  
**OBJECTIVES** ............................................................................................................................... 3  
**METHODS** .................................................................................................................................... 3  
  SITE ELIGIBILITY .............................................................................................................................. 3  
  SURVEILLANCE DESIGN .................................................................................................................. 4  
  SURVEILLANCE PERIOD .................................................................................................................. 4  
  NUMERATORS .................................................................................................................................... 4  
    *Inpatient antimicrobial usage* ................................................................................................. 4  
  DENOMINATORS ............................................................................................................................. 4  
    *Patient-day denominators* ........................................................................................................ 4  
  **TABLE 1:** MANDATORY AND REQUESTED DATA ELEMENTS ............................................. 5  
  DATA SUBMISSION .......................................................................................................................... 6  
    *Format* ......................................................................................................................................... 6  
  ANALYSIS .......................................................................................................................................... 6  
**ETHICS** ........................................................................................................................................ 6  
**APPENDIX 1 – BREAKDOWN BY WARD-TYPE** ........................................................................... 7  
**APPENDIX 2 – EXAMPLE TEMPLATES FOR DATA SUBMISSION** ........................................... 8  
**APPENDIX 3 – ATC CODES AND DDDS FOR ALL SYSTEMIC ANTIMICROBIALS** ................. 10  
**REFERENCES** ................................................................................................................................. 12  
**REVISION HISTORY** ..................................................................................................................... 13
BACKGROUND

There is a well-documented association between antimicrobial (or antibiotic) use and the emergence of antimicrobial resistant pathogens (AMR) (Canton R 2011). Antimicrobial stewardship, which includes the appropriate selection, dosing, route, and duration of antimicrobial therapy, is an important component of infection control and patient safety. Effective antimicrobial stewardship and comprehensive infection prevention and control programs have been shown to limit the emergence and transmission of AMR including, but not limited to, Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE) and Carbapenem-resistant Gram-negative organisms (Lawes T 2016, Molina 2017).

National data on AMU in Canadian hospitals are limited. Taylor et al. reported on the prevalence of AMU within a network of Canadian hospitals from 2002 and 2009 (Taylor 2015). These data provide cross-sectional antimicrobial dispensing results from 28 and 44 hospitals, respectively. Data collected in the Canadian Drug Store and Hospital Purchases (CDH) Dataset (administered by IQVIA) captures the national quantity of antimicrobials purchased by the hospital sector (i.e., acute-care, long-term care, government redistribution centers, and government facilities), but relies on proprietary projection methods and does not directly measure antimicrobial dispensation.

To address this knowledge gap, the Canadian Nosocomial Infection Surveillance Program (CNISP) antimicrobial usage study collects AMU data from participating sentinel sites. Since CNISP collects AMU data directly from CNISP hospital pharmacies, CNISP AMU data is more robust than other sources of AMU information representing consumption in acute care hospitals. These data are analyzed using Defined Daily Doses (DDDs) or days-of-therapy (DOTs) for pediatrics as per the World Health Organization’s guidelines, allowing for comparisons within Canada and internationally. Since CNISP collects data on both AMU and AMR, by linking the AMU and AMR data, CNISP will be able to estimate the magnitude and impact of AMU and AMR in tertiary acute care hospitals in Canada. CNISP uses these data to monitor trends and provide valuable information to health care providers and policy makers to aid in the control of AMR and the promotion of appropriate antimicrobial use.

OBJECTIVES

1. Estimate national and regional antimicrobial utilization (AMU) and provide benchmarks based on data received through participating CNISP hospitals.
2. Estimate rates of antimicrobial utilization by specific ward-type (including ICU and non-ICU wards; medical, surgical, combined, ICU and other ward types)
3. Evaluate trends and patterns of AMR across Canada and identify whether a correlation between CNISP AMU data and CNISP AMR data can be established.

METHODS

Site Eligibility

Sites that are able to provide the following mandatory fields (also outlined in Table 1) are eligible to participate in CNISP’s AMU surveillance.

1. **Numerator:** Acute-care inpatient antimicrobial usage (separated by adult and pediatric populations, by parenteral and oral administration routes, and by ICU and non-ICU ward types).
2. **Denominator:** Patient-day denominators by ward type (please use the same ward types/groups of wards as your numerator data).
**Surveillance Design**

AMU surveillance is ongoing and optional for hospitals participating in CNISP.

CNISP collects annual AMU data for all inpatients at participating hospitals. The AMU data may be separated by individual hospital ward or by groups of wards. For each hospital ward or group of wards that are used to submit AMU data to CNISP, participating hospitals must also provide an associated patient-day denominator for that ward or group of wards.

CNISP collects information on antibiotic use among acute adult and pediatric inpatients. This surveillance includes the following antimicrobials:
- All systemic antibacterials (all ‘J01’ ATC codes)
- Metronidazole oral (‘P01AB01’ ATC code)
- Vancomycin oral (‘A07AA09’ ATC code)

Full list of the included ATC codes: [APPENDIX 3 – ATC CODES AND DDDS FOR ALL SYSTEMIC ANTIMICROBIALS](#).

**Surveillance period**

Data are retrospectively collected. Annual calendar-year data are due by March 31st of the subsequent year.

*Example:* Data from January 1st 2020 to December 31st 2020 are due by March 31st 2021 as part of the 2021 Surveillance period.

**Numerator (AMU)**

**Denominator (patient-days)**

Data Retrospectively Collected (previous year)  
Jan 1st – Dec 31st  
Data Due (current year)  
March 31st

If you have any questions please do not hesitate to contact us [phac.cnisp-pcsin.aspc@canada.ca](mailto:phac.cnisp-pcsin.aspc@canada.ca)

**Numerators**

**Inpatient antimicrobial usage**

AMU separated by adult and pediatric populations, by parenteral and oral administration routes, and by ICU vs non-ICU wards. Pediatric AMU data is collected in days of therapy. Sites may submit adult AMU data as ‘quantities of antimicrobial used’ (e.g. in grams/MU) and/or as defined daily doses (DDD); it is requested that sites submit quantity data so that changes in DDD values can be accounted for over time. Please note that:

- a) ER patients that are admitted as inpatients are to be included in the ‘other’ or ‘Non-ICU’ category (depending on your data submission format) for both the AMU and patient days data.
- b) Units/wards designated as Long-term Care (LTC) units should not be included in the AMU or patient days data.

**Denominators**

**Patient-day denominators**

Patient-days for all ward/ward groups used for submitting the above AMU data.

**Antimicrobial Stewardship Programs**

Starting in 2021, hospitals are requested to complete the three questions listed in Appendix 4 and submit responses via email when submitting their AMU data.
### Table 1: Mandatory and Requested Data Elements

<table>
<thead>
<tr>
<th>Variable</th>
<th>Adults</th>
<th>Pediatrics</th>
<th>Description of variable</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimicrobial usage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug name</td>
<td>MANDATORY</td>
<td>MANDATORY</td>
<td>Generic drug name for drugs meeting inclusion criteria:</td>
<td></td>
</tr>
<tr>
<td>ATC code</td>
<td>REQUESTED</td>
<td>REQUESTED</td>
<td>ATC code</td>
<td></td>
</tr>
<tr>
<td>Dose form or route</td>
<td>MANDATORY</td>
<td>MANDATORY</td>
<td>Identify dose form or route: Parenteral, or oral</td>
<td>If providing DDDs, please use Appendix 1 for consistency. Please note that 2019 data should be converted using the 2019 ATC Index. If providing DDDs is not feasible, strength and quantity information can be provided instead (eg. Provide quantity of antimicrobial used).</td>
</tr>
<tr>
<td>Quantity of antimicrobial used (preferred) AND/OR Defined Daily Doses (DDDs)</td>
<td>MANDATORY</td>
<td>MANDATORY</td>
<td>Defined Daily Doses (DDDs):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- The assumed average maintenance dose per day for a drug used for its main indication in adults** as specified by the WHO**</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Quantity of antimicrobial used:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Weight of drug used (grams, mgs, or million units)</td>
<td></td>
</tr>
<tr>
<td><strong>Unit of measure</strong></td>
<td>MANDATORY</td>
<td></td>
<td>Unit used for antimicrobial usage measure (DDDs, grams, milligrams, or million units)</td>
<td>If number of ‘tablets’ is provided, include dosage information.</td>
</tr>
<tr>
<td><strong>Days of Therapy (DOTs)</strong></td>
<td>REQUESTED</td>
<td>MANDATORY</td>
<td>The duration of antimicrobial usage. The number of days that a patient receives an antimicrobial agent (regardless of dose). Any antibiotic dose that is received during a 24-hour period represents 1 DOT. The DOT for a given patient on multiple antibiotics will be the sum of DOT for each antibiotic that the patient is receiving.</td>
<td>For patients that are transferred during the day to a new unit, the DOT is not split. The DOT for that day is recorded for the ward where the patient was transferred from and the following day the DOT is associated with the new ward.</td>
</tr>
<tr>
<td><strong>Length of Therapy (LOTs)</strong></td>
<td>REQUESTED</td>
<td></td>
<td>The number of days that a patient receives systemic antimicrobial agents, irrespective of the number of different drugs.</td>
<td>LOT will be lower than or equal to DOT because each antibiotic received is its own DOT.</td>
</tr>
<tr>
<td><strong>Antimicrobial Free-Days</strong></td>
<td>REQUESTED</td>
<td></td>
<td>The number of days that antimicrobial agents were NOT received during a given period on a given hospital unit.</td>
<td>AFD is calculated irrespective of the number of antimicrobial agents received.</td>
</tr>
<tr>
<td><strong>Pep.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age group</td>
<td>MANDATORY</td>
<td>MANDATORY</td>
<td>Adult or Pediatric</td>
<td>Where possible to separate individual patients by age, adults are defined as patients ≥18 yrs of age and pediatric patients are those &lt; 18 yrs of age. Where not possible to separate individual patients by age, wards may be separated based on the age group of the majority of patients.</td>
</tr>
<tr>
<td>ICU vs Non-ICU</td>
<td>MANDATORY</td>
<td>MANDATORY</td>
<td>Identify ward type: Non-ICU, ICU, CCU, PICU, PICICU, or NICU</td>
<td>ICU includes stand-alone medical, surgical or any ICUs with a combination of patient types e.g. med/surg; trauma/surgical; neuro, surgical, trauma, burn etc.</td>
</tr>
<tr>
<td><strong>Ward information</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ward type ( ^2 )</td>
<td>REQUESTED</td>
<td>REQUESTED</td>
<td>Identify ward type where available and applicable for your institution:</td>
<td>- Ward categories must be mutually exclusive.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Medical ward (excluding obstetrics/psychiatry)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Surgical ward</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Combined (medical/surgical) ward</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Hematology-OncoLOGY Unit*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Transplant Unit* (if possible separate bone marrow transplant and solid organ transplant units)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Burn Unit*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- ICU, NICU, PICU, PCICU or CCU</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Other ( ^2 ) (Obstetrics; Psychiatry and mental health units; Emergency (if inpatient/i.e., admitted); Other not listed above)</td>
<td></td>
</tr>
<tr>
<td><strong>Inpatient-Days</strong></td>
<td>MANDATORY</td>
<td>MANDATORY</td>
<td>Sites will provide inpatient days for January 1, 2019 to December 31, 2019 separated into adult and pediatric, and ward-type specific patient-days.</td>
<td>For each ward type the site is able to calculate antimicrobial usage, a denominator must be provided.</td>
</tr>
</tbody>
</table>

---

1 Source: PHO ASP Metrics Examples

2 Please note that 1. ER patients that are admitted as inpatients are to be included in the ‘other’ or ‘Non-ICU’ category depending on your data submission for both the AMU and patient days. 2. Units/wards designated as Long-term Care (LTC) units should not be included in the AMU or patient days.
Data Submission
To meet the objectives of the study, AMU data separated by specific ward-type (see Table 1 for list of mandatory and requested data elements) and the associated patient-day data are requested.

All data must be submitted to CNISP by email (phac.cnisp-pcsin.aspc@canada.ca). AMU and patient-day data are due by March 31st.

Format
Excel format is preferred following one of the example templates found in Appendix 2 – Example Templates for Data Submission.

If another submission format is easier for your hospital site, please contact CNISP (phac.cnisp-pcsin.aspc@canada.ca) to confirm that the format contains the necessary data elements.

For sites that submit ward-level information, please provide us with a data dictionary for your wards so that we can identify the type of ward (for example, indicating whether ‘6E’ is a medical or surgical ward). This data dictionary may be included as a variable in the dataset (preferred) or may be provided as a separate document.

Analysis
PHAC will be responsible for converting data files into a common platform and merging files for analysis. Individual site-specific as well as ICU vs non-ICU, oral vs. parental, regional and national adult rates will be calculated and standardized by 1000 patient days.

For adult surveillance, if sites have not submitted DDDs, PHAC will convert quantities to WHO DDDs (see Table 2). The following drugs are special cases:

- For benzylpenicillin (J01CE01), also known as penicillin G, and benzathine benzylpenicillin (J01CE08), data received in million units (MU) will be converted to grams (where 0.6 g = 1 MU), which can then be converted to DDDs using WHO values.
- Methenamine (J01XX05) is further divided into mandelate and hippurate, which have different DDDs: 3 g per DDD and 2 g per DDD, respectively.
- Erythromycin (J01FA01) can also be categorized as either erythromycin and erythromycin ethylsuccinate, both of which have different DDDs: 1 g per DDD and 2 g per DDD, respectively.

Data analysis for pediatric patients will be addressed differently as the dose given to pediatrics is adjusted by weight and there is no single DDD; thus, WHO suggests DOT as the appropriate measure to monitor trends of antimicrobials in children. The rates will be adjusted by the number of patient days in pediatrics sites.

ETHICS
While this surveillance project does not involve any alteration in patient care, ethics approval may be sought at some hospital sites. There are no patient identifiers in this data and data is aggregated with the lowest level of aggregation being at the hospital ward. All data submitted to PHAC is kept strictly confidential.
Appendix 1 – Breakdown by Ward-type

### Inpatient Acute-care Ward Breakdown

<table>
<thead>
<tr>
<th>Level</th>
<th>ICU</th>
<th>NICU (for peds)</th>
<th>PICU (for peds)</th>
<th>Combined (medical/surgical)</th>
<th>Surgical</th>
<th>Medical</th>
<th>Hem onc</th>
<th>Burn unit</th>
<th>Transplant</th>
<th>CCU</th>
<th>Ob/Gyn</th>
<th>Psych.</th>
<th>Etc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level 2</td>
<td>ICU</td>
<td>NICU (for peds)</td>
<td>PICU (for peds)</td>
<td>Combined (medical/surgical)</td>
<td>Surgical</td>
<td>Medical</td>
<td>Hem onc</td>
<td>Burn unit</td>
<td>Transplant</td>
<td>CCU</td>
<td>Ob/Gyn</td>
<td>Psych.</td>
<td>Etc.</td>
</tr>
<tr>
<td>Level 3</td>
<td>ICU</td>
<td>NICU</td>
<td>PICU</td>
<td>Combined (medical/surgical)</td>
<td>Surgical</td>
<td>Medical</td>
<td>Hem onc</td>
<td>Burn unit</td>
<td>Transplant</td>
<td>CCU</td>
<td>Ob/Gyn</td>
<td>Psych.</td>
<td>Etc.</td>
</tr>
</tbody>
</table>

**Notes:**
- If unable to breakdown further than level 1 and you have both adult ICUs, and PICU or NICU, please indicate what types of ICUs are included in your submission.
- Combined = combined medical/surgical wards
- “Other” wards can include any Non-ICU acute-care wards (Psychiatry, Ob/Gyn, etc.)
- If possible, breakdown by all individual ward types is appreciated (level 3)

Where possible, please indicate the wards included at all levels. If submitting data at levels 1 or 2, please include a note indicating what wards you submitted data for. e.x. Non-ICU included: Medical, Surgical, combined, and Ob/Gyn wards.
Appendix 2 – Example Templates for Data Submission
Sites may submit data in a variety of formats. Some examples of possible submission formats are below. It is preferred that sites submit data in similar formats each year.

Table 2: Example submission format for adult data – hospital calculating DDDs

<table>
<thead>
<tr>
<th>Ward type</th>
<th>Drug Name</th>
<th>Route</th>
<th>DDD</th>
<th>DOT (optional)</th>
<th>Patient-days for the ward-type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>Ciprofloxacin</td>
<td>P</td>
<td>165</td>
<td></td>
<td>1992</td>
</tr>
<tr>
<td>Medical</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>117</td>
<td></td>
<td>1992</td>
</tr>
<tr>
<td>Surgical</td>
<td>Ciprofloxacin</td>
<td>P</td>
<td>195</td>
<td></td>
<td>3941</td>
</tr>
<tr>
<td>Surgical</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>54</td>
<td></td>
<td>3941</td>
</tr>
<tr>
<td>ICU</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>175</td>
<td></td>
<td>545</td>
</tr>
<tr>
<td>CCU</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>175</td>
<td></td>
<td>345</td>
</tr>
<tr>
<td>Combined (Medical/Surgical)</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>180</td>
<td></td>
<td>654</td>
</tr>
<tr>
<td>Other - BMT</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>123</td>
<td></td>
<td>212</td>
</tr>
<tr>
<td>Other - Psychiatry</td>
<td>Ciprofloxacin</td>
<td>O</td>
<td>12</td>
<td></td>
<td>697</td>
</tr>
</tbody>
</table>

Table 3: Example submission format for adult data – hospital providing quantity and units

<table>
<thead>
<tr>
<th>Ward type</th>
<th>Drug Name</th>
<th>Route</th>
<th>Quantity</th>
<th>Units</th>
<th>DOT (optional)</th>
<th>Patient-days for the ward-type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>Amoxicillin</td>
<td>P</td>
<td>455</td>
<td>Gr</td>
<td></td>
<td>1992</td>
</tr>
<tr>
<td>Medical</td>
<td>Amoxicillin</td>
<td>O</td>
<td>375</td>
<td>Gr</td>
<td></td>
<td>1992</td>
</tr>
<tr>
<td>Surgical</td>
<td>Amoxicillin</td>
<td>P</td>
<td>295</td>
<td>Gr</td>
<td></td>
<td>3941</td>
</tr>
<tr>
<td>ICU</td>
<td>Amoxicillin</td>
<td>O</td>
<td>155</td>
<td>Gr</td>
<td></td>
<td>545</td>
</tr>
<tr>
<td>CCU</td>
<td>Amoxicillin</td>
<td>O</td>
<td>17500</td>
<td>Mg</td>
<td></td>
<td>345</td>
</tr>
<tr>
<td>Combined (Medical/Surgical)</td>
<td>Amoxicillin</td>
<td>O</td>
<td>180</td>
<td>Gr</td>
<td></td>
<td>654</td>
</tr>
<tr>
<td>Other - BMT</td>
<td>Amoxicillin</td>
<td>O</td>
<td>123</td>
<td>Gr</td>
<td></td>
<td>212</td>
</tr>
</tbody>
</table>

Table 4: Example submission format for pediatric data – hospital providing DOTs

<table>
<thead>
<tr>
<th>Ward type</th>
<th>Drug Name</th>
<th>Route</th>
<th>DOT</th>
<th>Patient-days for the ward-type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>Pip-tazo</td>
<td>P</td>
<td>512</td>
<td>1605</td>
</tr>
<tr>
<td>Medical</td>
<td>Pip-tazo</td>
<td>O</td>
<td>125</td>
<td>1605</td>
</tr>
<tr>
<td>Surgical</td>
<td>Pip-tazo</td>
<td>P</td>
<td>454</td>
<td>3941</td>
</tr>
<tr>
<td>Other - Transplant</td>
<td>Pip-tazo</td>
<td>O</td>
<td>545</td>
<td>345</td>
</tr>
<tr>
<td>PICU</td>
<td>Pip-tazo</td>
<td>O</td>
<td>455</td>
<td>654</td>
</tr>
<tr>
<td>NICU</td>
<td>Pip-tazo</td>
<td>O</td>
<td>212</td>
<td>212</td>
</tr>
<tr>
<td>Other - Psychiatry</td>
<td>Pip-tazo</td>
<td>O</td>
<td>24</td>
<td>343</td>
</tr>
</tbody>
</table>
Table 5: Example submission format for adult data – hospitals provide patient days in separate tab

<table>
<thead>
<tr>
<th>Ward</th>
<th>Drug Name</th>
<th>Route</th>
<th>Quantity</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>M8</td>
<td>Amoxicillin</td>
<td>P</td>
<td>455</td>
<td>Gr</td>
</tr>
<tr>
<td>M8</td>
<td>Amoxicillin</td>
<td>O</td>
<td>375</td>
<td>Gr</td>
</tr>
<tr>
<td>SURG</td>
<td>Amoxicillin</td>
<td>P</td>
<td>295</td>
<td>Gr</td>
</tr>
<tr>
<td>ICU</td>
<td>Amoxicillin</td>
<td>O</td>
<td>155</td>
<td>Gr</td>
</tr>
<tr>
<td>CCU</td>
<td>Amoxicillin</td>
<td>O</td>
<td>17500</td>
<td>Mg</td>
</tr>
<tr>
<td>FE</td>
<td>Amoxicillin</td>
<td>O</td>
<td>180</td>
<td>Gr</td>
</tr>
<tr>
<td>S9</td>
<td>Amoxicillin</td>
<td>O</td>
<td>123</td>
<td>Gr</td>
</tr>
</tbody>
</table>

Tab 1 – AMU by ward

<table>
<thead>
<tr>
<th>Ward type</th>
<th>Ward</th>
<th>Patient-days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>M8</td>
<td>1992</td>
</tr>
<tr>
<td>Surgical</td>
<td>SURG</td>
<td>3941</td>
</tr>
<tr>
<td>ICU</td>
<td>ICU</td>
<td>545</td>
</tr>
<tr>
<td>CCU</td>
<td>CCU</td>
<td>345</td>
</tr>
<tr>
<td>Combined (Medical/Surgical)</td>
<td>FE</td>
<td>654</td>
</tr>
<tr>
<td>Other - BMT</td>
<td>S9</td>
<td>212</td>
</tr>
</tbody>
</table>

Tab 2 – Data dictionary and patient-days
Appendix 3 – ATC codes and DDDs for all Systemic Antimicrobials

Table 6:

2020 ATC Index.xlsx
Appendix 4 – Antimicrobial Stewardship Program Questions

Requested responses to be submitted with AMU data (phac.cnisp-pcsin.aspc@canada.ca)

1. For which hospitals are you submitting responses? (If hospitals have different antimicrobial stewardship programs, please respond separately for each hospital): ________________________________

2. Do you currently have a formal Antimicrobial Stewardship Program (ASP) at your hospital site/network? (This could be with or without designated funding/resources)
   - ☐ Yes, if yes, in what year was it formalized?: ______ (yyyy)
   - ☐ We are in the process of implementing/planning to implement an ASP in the next 12 months
   - ☐ There are currently no plans to implement

3. Are there designated funding/resources for your ASP?
   - ☐ N/A (no current ASP)
   - ☐ No
   - ☐ Yes, if yes, please specify the amount of full time equivalent (FTE) dedicated to ASP for each of the following:
     - ☐ Pharmacists - # of FTE: ______
     - ☐ Physicians - # of FTE: ______
     - ☐ Nurses - # of FTE: ______
     - ☐ Infection control professionals - # of FTE: ______
     - ☐ Information Technology professionals - # of FTE: ______
     - ☐ Other (please specify role and # of FTE): ______
     - ☐ No dedicated FTE for specific positions
References


<table>
<thead>
<tr>
<th>Date</th>
<th>Revisions Made</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2018</td>
<td>1. Will only accept AMU data as dispensed or administered (not purchased) – have removed this as an option from Appendix 3 – pt-days submission form (p. 11) and clarified it in the numerator data (p. 3)</td>
</tr>
<tr>
<td></td>
<td>2. Have asked that CCU data be separated (as an optional variable) (p.4, Appendices 2 &amp; 3)</td>
</tr>
<tr>
<td></td>
<td>3. Have asked that type of ICU(s) be specified (if possible) (p.4, Appendices 2 &amp; 3)</td>
</tr>
<tr>
<td></td>
<td>4. For co-trimoxazole (J01EE01) WHO does provide the DDD – so have removed this comment (p.4)</td>
</tr>
<tr>
<td></td>
<td>5. Have corrected the WHO DDD unit for Trimethoprim/ Sulfamethoxazole (Co-trimoxazole) (parenteral &amp; oral) (p. 7)</td>
</tr>
<tr>
<td></td>
<td>6. As the inclusion criteria specified the collection of only systemic antibacterials (J01) the following inhaled powders and solutions have been removed from both the protocol and the data collection form (excel) and the data are no longer required to be submitted</td>
</tr>
<tr>
<td></td>
<td>Aztreonam J01DF01 Inhaled solution</td>
</tr>
<tr>
<td></td>
<td>Tobramycin J01GB01 Inhaled solution</td>
</tr>
<tr>
<td></td>
<td>Tobramycin J01GB01 Inhaled powder</td>
</tr>
<tr>
<td></td>
<td>Colistin J01XB01 Inhaled solution</td>
</tr>
<tr>
<td>October 2018</td>
<td>1. Added hem/onc, transplant, bone marrow transplant, solid organ transplant separations to the other category.</td>
</tr>
<tr>
<td></td>
<td>2. Clarified age break point for adults/peds</td>
</tr>
<tr>
<td></td>
<td>3. Created table of requested and mandatory variables.</td>
</tr>
<tr>
<td>December 2018</td>
<td>1. Added references</td>
</tr>
<tr>
<td></td>
<td>2. Removed Appendix 3 and created new example templates</td>
</tr>
<tr>
<td>August 2019</td>
<td>1. Updated DDD values to the 2019 WHO values.</td>
</tr>
<tr>
<td></td>
<td>2. Clarified the details of the ward transferred</td>
</tr>
<tr>
<td></td>
<td>3. Changed ‘due’ date of data to March.</td>
</tr>
<tr>
<td>December 2019</td>
<td>1. Updated protocol format</td>
</tr>
<tr>
<td></td>
<td>2. Added appendix 1</td>
</tr>
<tr>
<td></td>
<td>3. Added Table 5 in appendix 2</td>
</tr>
<tr>
<td></td>
<td>4. Updated Surveillance period (removed years), changed submission date from June to March 31st</td>
</tr>
<tr>
<td>November 2020</td>
<td>1. Updated DDD values for 2020</td>
</tr>
<tr>
<td></td>
<td>2. Added stewardship questions.</td>
</tr>
</tbody>
</table>